Skip to content
About Us
Exploring Antibodies, Creating Novel Biologics

Greeting from CEO

Young Woo Park

Y-Biologics is a biotechnology company focused on the discovery of antibody therapeutics with proprietary platform technologies. We have secured own fully human antibody library,
Ymax®-ABL (See more) , with phage display technology and have generated several antibody pipelines in various modalities. Furthermore, we have developed novel T cell bispecific antibody platform technology, ALiCE (Antibody Like Cell Engager) which has potential to address current unmet needs in fields of immuno-oncology.

Based on our experiences and expertise, we would like to provide antibody discovery services globally. We shall continue our innovation not only to develop antibody therapeutics but also will contribute to the global biotech industry as a leading biopharmaceutical company in the fields of immuno-oncology.

As a reliable service provider, Y-Biologics will guide your journey for generating antibodies with high quality. We keep trying to pursue the best results by fully utilizing our techniques and resources to complete the client’s projects. Besides, we offer bespoke services based on the purpose of research and specific requests of the clients.

 

To learn more about Y-Biologics, visit our company website:

START UP

Constructed fully human antibody library platform

  • Fully human antibody library platform
  • Protein production platform using mammalian cells
START UP

Constructed fully human antibody library platform

  • Fully human antibody library platform
  • Protein production platform using mammalian cells

Verification

Strengthen competitiveness in antibody discovery targeted
for immuno-oncology therapeutics
  • Discovered human anti PD-1 and PD-L1 antibody
  • Confirmed quality of fully human antibody library by securing various pipelines of immuno-oncology therapeutics
  • Attracted $1.2 million investment
Leap Forward
Building up T cell bispecific antibody based on ALiCETM technology
  • Development of novel T cell bispecific antibody platform technology (ALiCETM)
  • Attracted additional investment $3.1 million
  • Licensing out
  • Preparation of listing
Sustainable Growth
Business expansion through listing
  • Completion of listing
  • Entering clinical trials of 2-3 T cell bispecific antibody pipelines
Start up
Growing
Developing
Thriving